Pacira BioSciences (PCRX) Short-term Investments (2011 - 2026)

Pacira BioSciences' Short-term Investments history runs 16 years deep, the most recent figure standing at $57.9 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 72.44% year-over-year to $57.9 million in Q1 2026; TTM through Mar 2026 was $57.9 million, a 72.44% decrease from a year earlier, with the FY2025 full-year figure at $79.9 million, down 61.57% from the prior year.
• Short-term Investments slipped to $57.9 million in Q1 2026 per PCRX's latest filing, from $79.9 million in the prior quarter.
• Across five years, Short-term Investments topped out at $225.4 million in Q1 2022 and bottomed at $57.9 million in Q1 2026.
• The 5-year median for Short-term Investments is $145.4 million (2025), against an average of $156.7 million.
• Across the five-year window, Short-term Investments jumped 160.5% in 2022 and plunged 72.44% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $184.5 million in 2022, then sank by 32.1% to $125.3 million in 2023, then soared by 65.9% to $207.8 million in 2024, then sank by 61.57% to $79.9 million in 2025, then slipped by 27.55% to $57.9 million in 2026.
• Per Business Quant, the three latest PCRX Short-term Investments figures stand at $57.9 million (Q1 2026), $79.9 million (Q4 2025), and $98.7 million (Q3 2025).